Artificial Pancreas Device System Market Report 2026

Artificial Pancreas Device System Market Overview

• Artificial Pancreas Device System market size has reached to $2.06 billion in 2025 • Expected to grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: Impact Of Increasing Pancreatic Cancer Prevalence On The Artificial Pancreas Device System Market • Market Trend: Innovations in Automated Insulin Delivery Systems • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Pancreas Device System Market?

Artificial pancreas device system (APDS) is a medical technology designed to automate blood glucose control for individuals with diabetes. The system integrates continuous glucose monitoring (CGM) with an insulin pump, and uses a sophisticated algorithm to automatically adjust insulin delivery based on real-time glucose readings. The device aims to mimic the glucose-regulating function of a healthy pancreas, thereby reducing the need for manual blood glucose monitoring and insulin injections, and helping to maintain blood glucose levels within a target range. The main types of devices in the artificial pancreas device system market are threshold suspend device systems, control-to-range systems, and control-to-target systems. Threshold suspend device systems refer to insulin pump technologies used in diabetes management that automatically suspend insulin delivery when blood glucose levels drop below a predefined threshold. The various treatment types include bi-hormonal, insulin only, and hybrid, and several end-users including hospitals, medical centers, and others.

What Is The Artificial Pancreas Device System Market Growth Forecast?

The artificial pancreas device system market size is expected to see rapid growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing demand for fully automated glucose regulation, rising investments in digital diabetes care, expansion of remote patient monitoring, growing focus on personalized insulin therapy, increasing regulatory support for advanced diabetes devices. Major trends in the forecast period include increasing adoption of closed-loop glucose control systems, rising integration of cgm with insulin pumps, growing use of predictive algorithms for insulin delivery, expansion of wearable diabetes management devices, enhanced focus on patient-centric automation.

Global Artificial Pancreas Device System Market Segmentation

1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems 2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid 3) By End-User: Hospitals, Medical Centers, Other End-Users Subsegments: 1) By Threshold Suspend Device Systems: Insulin Pump with Threshold Suspend, Continuous Glucose Monitoring (CGM) Integrated Systems 2) By Control-To-Range Systems: Hybrid Closed-Loop Systems, Insulin Delivery Systems with Range Control, Real-Time Glucose Adjustment Systems 3) By Control-To-Target Systems: Fully Closed-Loop Artificial Pancreas Systems, Insulin Pumps with Targeted Glucose Control, Automated Glucose Regulation Systems

What Is The Driver Of The Artificial Pancreas Device System Market?

The increasing prevalence of pancreatic cancer is expected to propel the growth of the artificial pancreas device system market going forward. Pancreatic cancer is a malignant tumor that originates in the pancreas, a gland located behind the stomach. Pancreatic cancer is influenced by a combination of lifestyle, genetic, medical, and environmental factors, along with genetic mutations causing hereditary pancreatitis, which can lead to chronic inflammation of the pancreas. An artificial pancreas device system (APDS) is primarily designed to help individuals with diabetes manage their blood sugar levels by automatically monitoring glucose and delivering the appropriate amount of insulin. For instance, in March 2024, Cancer Australia, a government agency, estimated that 4,506 new cases of pancreatic cancer were diagnosed in 2023, an increase from the 3,751 cases reported over the past five years. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the artificial pancreas device system industry.

Key Players In The Global Artificial Pancreas Device System Market

Major companies operating in the artificial pancreas device system market are Medtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, MicroTech Medical

Global Artificial Pancreas Device System Market Trends and Insights

Major companies operating in the artificial pancreas device system market are developing automated insulin delivery systems to enhance diabetes management by automatically monitoring blood glucose levels and delivering the appropriate amount of insulin. Automated insulin delivery systems aim to replicate the function of a healthy pancreas, reducing the burden of constant blood sugar monitoring and manual insulin administration for individuals with diabetes. For instance, in May 2023, Beta Bionics, a US-based medical equipment manufacturing company, received FDA 510(k) clearance for iLet Insulin-Only Bionic Pancreas System, an automated insulin delivery device. It is an artificial pancreas system designed to autonomously determine and deliver insulin doses to control blood glucose levels. A closed-loop system automatically adjusts insulin delivery based on the user's glucose levels measured by a connected continuous glucose monitor (CGM). It only requires the user's body weight and a meal size estimate to adjust insulin delivery automatically.

What Are Latest Mergers And Acquisitions In The Artificial Pancreas Device System Market?

In September 2023, Abbott Laboratories, a US-based pharmaceutical company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition enhances Abbott's footprint in diabetes care by leveraging its world-leading Freestyle Libre portfolio of continuous glucose monitoring technology. It also advances the company's mission to create connected solutions that make diabetes management more personalized and precise. Bigfoot Biomedical is a US-based company that specializes in developing prototype of automated insulin delivery systems, known as artificial pancreas,

Regional Outlook

North America was the largest region in the artificial pancreas device system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Pancreas Device System Market?

The artificial pancreas device system market includes revenues earned by entities by providing services such as patient monitoring, device maintenance, data management, software updates, healthcare provider consultations, and training and support for patients and healthcare professionals. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial pancreas device system market also includes sales of insulin pumps, continuous glucose monitors, control algorithms and software applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Pancreas Device System Market Report 2026?

The artificial pancreas device system market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial pancreas device system industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.